Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 102

Published Date: 15 Jan 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Companies Mentioned
  • sp_icon1 sp_icon1_b Related Reports
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine.

According to our (Global Info Research) latest study, the global Gastrointestinal Stromal Tumors (GSTs) Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Gastrointestinal Stromal Tumors (GSTs) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gastrointestinal Stromal Tumors (GSTs) Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gastrointestinal Stromal Tumors (GSTs) Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Bayer, Novartis, Immunicum and Roche, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Gastrointestinal Stromal Tumors (GSTs) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Surgery
Targeted Therapy
Radiation Therapy
ChemOthersapy
Others

Market segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Market segment by players, this report covers
Pfizer
Bayer
Novartis
Immunicum
Roche
AB Science
Arog Pharmaceuticals
Boston Biomedical
Sun Pharmaceutical
Natco Pharma

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Gastrointestinal Stromal Tumors (GSTs) Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gastrointestinal Stromal Tumors (GSTs) Treatment, with revenue, gross margin and global market share of Gastrointestinal Stromal Tumors (GSTs) Treatment from 2018 to 2023.
Chapter 3, the Gastrointestinal Stromal Tumors (GSTs) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gastrointestinal Stromal Tumors (GSTs) Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Gastrointestinal Stromal Tumors (GSTs) Treatment.
Chapter 13, to describe Gastrointestinal Stromal Tumors (GSTs) Treatment research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Gastrointestinal Stromal Tumors (GSTs) Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gastrointestinal Stromal Tumors (GSTs) Treatment by Type
1.3.1 Overview: Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type in 2022
1.3.3 Surgery
1.3.4 Targeted Therapy
1.3.5 Radiation Therapy
1.3.6 ChemOthersapy
1.3.7 Others
1.4 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market by Application
1.4.1 Overview: Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Ambulatory Surgical Centers
1.4.5 Others
1.5 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size & Forecast
1.6 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast by Region
1.6.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region, (2018-2029)
1.6.3 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)

2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.1.4 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.2.4 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bayer Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.3.4 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Immunicum
2.4.1 Immunicum Details
2.4.2 Immunicum Major Business
2.4.3 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.4.4 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Immunicum Recent Developments and Future Plans
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business
2.5.3 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.5.4 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Roche Recent Developments and Future Plans
2.6 AB Science
2.6.1 AB Science Details
2.6.2 AB Science Major Business
2.6.3 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.6.4 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AB Science Recent Developments and Future Plans
2.7 Arog Pharmaceuticals
2.7.1 Arog Pharmaceuticals Details
2.7.2 Arog Pharmaceuticals Major Business
2.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.7.4 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Arog Pharmaceuticals Recent Developments and Future Plans
2.8 Boston Biomedical
2.8.1 Boston Biomedical Details
2.8.2 Boston Biomedical Major Business
2.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.8.4 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Boston Biomedical Recent Developments and Future Plans
2.9 Sun Pharmaceutical
2.9.1 Sun Pharmaceutical Details
2.9.2 Sun Pharmaceutical Major Business
2.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.9.4 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Sun Pharmaceutical Recent Developments and Future Plans
2.10 Natco Pharma
2.10.1 Natco Pharma Details
2.10.2 Natco Pharma Major Business
2.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.10.4 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Natco Pharma Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Gastrointestinal Stromal Tumors (GSTs) Treatment by Company Revenue
3.2.2 Top 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Players Market Share in 2022
3.2.3 Top 6 Gastrointestinal Stromal Tumors (GSTs) Treatment Players Market Share in 2022
3.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Overall Company Footprint Analysis
3.3.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Region Footprint
3.3.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Type Footprint
3.3.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
4.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value and Market Share by Type (2018-2023)
4.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
5.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2023)
5.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Forecast by Application (2024-2029)

6 North America
6.1 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
6.2 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
6.3 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
6.3.1 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

7 Europe
7.1 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
7.2 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
7.3 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
7.3.1 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.3 France Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region
8.3.1 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2018-2029)
8.3.2 China Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.5 India Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

9 South America
9.1 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
9.2 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
9.3 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
9.3.1 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
10.3.1 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

11 Market Dynamics
11.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers
11.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Restraints
11.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
12.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Industry Chain
12.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Upstream Analysis
12.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Midstream Analysis
12.4 Gastrointestinal Stromal Tumors (GSTs) Treatment Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Pfizer Company Information, Head Office, and Major Competitors
Table 6. Pfizer Major Business
Table 7. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 8. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Pfizer Recent Developments and Future Plans
Table 10. Bayer Company Information, Head Office, and Major Competitors
Table 11. Bayer Major Business
Table 12. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 13. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Bayer Recent Developments and Future Plans
Table 15. Novartis Company Information, Head Office, and Major Competitors
Table 16. Novartis Major Business
Table 17. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 18. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Novartis Recent Developments and Future Plans
Table 20. Immunicum Company Information, Head Office, and Major Competitors
Table 21. Immunicum Major Business
Table 22. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 23. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Immunicum Recent Developments and Future Plans
Table 25. Roche Company Information, Head Office, and Major Competitors
Table 26. Roche Major Business
Table 27. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 28. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Roche Recent Developments and Future Plans
Table 30. AB Science Company Information, Head Office, and Major Competitors
Table 31. AB Science Major Business
Table 32. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 33. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. AB Science Recent Developments and Future Plans
Table 35. Arog Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Arog Pharmaceuticals Major Business
Table 37. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 38. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Arog Pharmaceuticals Recent Developments and Future Plans
Table 40. Boston Biomedical Company Information, Head Office, and Major Competitors
Table 41. Boston Biomedical Major Business
Table 42. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 43. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Boston Biomedical Recent Developments and Future Plans
Table 45. Sun Pharmaceutical Company Information, Head Office, and Major Competitors
Table 46. Sun Pharmaceutical Major Business
Table 47. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 48. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Sun Pharmaceutical Recent Developments and Future Plans
Table 50. Natco Pharma Company Information, Head Office, and Major Competitors
Table 51. Natco Pharma Major Business
Table 52. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 53. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Natco Pharma Recent Developments and Future Plans
Table 55. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million) by Players (2018-2023)
Table 56. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Share by Players (2018-2023)
Table 57. Breakdown of Gastrointestinal Stromal Tumors (GSTs) Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Gastrointestinal Stromal Tumors (GSTs) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Gastrointestinal Stromal Tumors (GSTs) Treatment Players
Table 60. Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Type Footprint
Table 61. Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Application Footprint
Table 62. Gastrointestinal Stromal Tumors (GSTs) Treatment New Market Entrants and Barriers to Market Entry
Table 63. Gastrointestinal Stromal Tumors (GSTs) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Share by Type (2018-2023)
Table 66. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Forecast by Type (2024-2029)
Table 67. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023)
Table 68. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Forecast by Application (2024-2029)
Table 69. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Gastrointestinal Stromal Tumors (GSTs) Treatment Raw Material
Table 100. Key Suppliers of Gastrointestinal Stromal Tumors (GSTs) Treatment Raw Materials
List of Figures
Figure 1. Gastrointestinal Stromal Tumors (GSTs) Treatment Picture
Figure 2. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type in 2022
Figure 4. Surgery
Figure 5. Targeted Therapy
Figure 6. Radiation Therapy
Figure 7. ChemOthersapy
Figure 8. Others
Figure 9. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application in 2022
Figure 11. Hospitals Picture
Figure 12. Clinics Picture
Figure 13. Ambulatory Surgical Centers Picture
Figure 14. Others Picture
Figure 15. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Market Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 18. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 19. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Region in 2022
Figure 20. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 23. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Share by Players in 2022
Figure 26. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 27. Global Top 3 Players Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share in 2022
Figure 28. Global Top 6 Players Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share in 2022
Figure 29. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Share by Type (2018-2023)
Figure 30. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share Forecast by Type (2024-2029)
Figure 31. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Share by Application (2018-2023)
Figure 32. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share Forecast by Application (2024-2029)
Figure 33. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 34. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 35. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 37. Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 38. Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 39. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 40. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 41. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 42. Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. France Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 44. United Kingdom Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 45. Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 46. Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 47. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 48. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 49. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 50. China Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 52. South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 53. India Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 54. Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 55. Australia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 56. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 57. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 58. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 59. Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 60. Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 61. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 62. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 63. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 64. Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 65. Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 66. UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 67. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers
Figure 68. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Restraints
Figure 69. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Manufacturing Cost Structure Analysis of Gastrointestinal Stromal Tumors (GSTs) Treatment in 2022
Figure 72. Manufacturing Process Analysis of Gastrointestinal Stromal Tumors (GSTs) Treatment
Figure 73. Gastrointestinal Stromal Tumors (GSTs) Treatment Industrial Chain
Figure 74. Methodology
Figure 75. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Pfizer
Bayer
Novartis
Immunicum
Roche
AB Science
Arog Pharmaceuticals
Boston Biomedical
Sun Pharmaceutical
Natco Pharma
shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 102

Published Date: 15 Jan 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine.

According to our (Global Info Research) latest study, the global Gastrointestinal Stromal Tumors (GSTs) Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Gastrointestinal Stromal Tumors (GSTs) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Gastrointestinal Stromal Tumors (GSTs) Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gastrointestinal Stromal Tumors (GSTs) Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gastrointestinal Stromal Tumors (GSTs) Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Bayer, Novartis, Immunicum and Roche, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Gastrointestinal Stromal Tumors (GSTs) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Surgery
Targeted Therapy
Radiation Therapy
ChemOthersapy
Others

Market segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Market segment by players, this report covers
Pfizer
Bayer
Novartis
Immunicum
Roche
AB Science
Arog Pharmaceuticals
Boston Biomedical
Sun Pharmaceutical
Natco Pharma

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Gastrointestinal Stromal Tumors (GSTs) Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gastrointestinal Stromal Tumors (GSTs) Treatment, with revenue, gross margin and global market share of Gastrointestinal Stromal Tumors (GSTs) Treatment from 2018 to 2023.
Chapter 3, the Gastrointestinal Stromal Tumors (GSTs) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gastrointestinal Stromal Tumors (GSTs) Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Gastrointestinal Stromal Tumors (GSTs) Treatment.
Chapter 13, to describe Gastrointestinal Stromal Tumors (GSTs) Treatment research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Gastrointestinal Stromal Tumors (GSTs) Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gastrointestinal Stromal Tumors (GSTs) Treatment by Type
1.3.1 Overview: Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type in 2022
1.3.3 Surgery
1.3.4 Targeted Therapy
1.3.5 Radiation Therapy
1.3.6 ChemOthersapy
1.3.7 Others
1.4 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market by Application
1.4.1 Overview: Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Ambulatory Surgical Centers
1.4.5 Others
1.5 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size & Forecast
1.6 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast by Region
1.6.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region, (2018-2029)
1.6.3 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Prospect (2018-2029)

2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.1.4 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.2.4 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bayer Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.3.4 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Immunicum
2.4.1 Immunicum Details
2.4.2 Immunicum Major Business
2.4.3 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.4.4 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Immunicum Recent Developments and Future Plans
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business
2.5.3 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.5.4 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Roche Recent Developments and Future Plans
2.6 AB Science
2.6.1 AB Science Details
2.6.2 AB Science Major Business
2.6.3 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.6.4 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AB Science Recent Developments and Future Plans
2.7 Arog Pharmaceuticals
2.7.1 Arog Pharmaceuticals Details
2.7.2 Arog Pharmaceuticals Major Business
2.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.7.4 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Arog Pharmaceuticals Recent Developments and Future Plans
2.8 Boston Biomedical
2.8.1 Boston Biomedical Details
2.8.2 Boston Biomedical Major Business
2.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.8.4 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Boston Biomedical Recent Developments and Future Plans
2.9 Sun Pharmaceutical
2.9.1 Sun Pharmaceutical Details
2.9.2 Sun Pharmaceutical Major Business
2.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.9.4 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Sun Pharmaceutical Recent Developments and Future Plans
2.10 Natco Pharma
2.10.1 Natco Pharma Details
2.10.2 Natco Pharma Major Business
2.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
2.10.4 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Natco Pharma Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Gastrointestinal Stromal Tumors (GSTs) Treatment by Company Revenue
3.2.2 Top 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Players Market Share in 2022
3.2.3 Top 6 Gastrointestinal Stromal Tumors (GSTs) Treatment Players Market Share in 2022
3.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Overall Company Footprint Analysis
3.3.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Region Footprint
3.3.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Type Footprint
3.3.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
4.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value and Market Share by Type (2018-2023)
4.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
5.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2023)
5.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Forecast by Application (2024-2029)

6 North America
6.1 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
6.2 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
6.3 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
6.3.1 North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

7 Europe
7.1 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
7.2 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
7.3 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
7.3.1 Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.3 France Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Region
8.3.1 Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2018-2029)
8.3.2 China Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.5 India Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

9 South America
9.1 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
9.2 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
9.3 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
9.3.1 South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size by Country
10.3.1 Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size and Forecast (2018-2029)

11 Market Dynamics
11.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers
11.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Restraints
11.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
12.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Industry Chain
12.2 Gastrointestinal Stromal Tumors (GSTs) Treatment Upstream Analysis
12.3 Gastrointestinal Stromal Tumors (GSTs) Treatment Midstream Analysis
12.4 Gastrointestinal Stromal Tumors (GSTs) Treatment Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Pfizer Company Information, Head Office, and Major Competitors
Table 6. Pfizer Major Business
Table 7. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 8. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Pfizer Recent Developments and Future Plans
Table 10. Bayer Company Information, Head Office, and Major Competitors
Table 11. Bayer Major Business
Table 12. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 13. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Bayer Recent Developments and Future Plans
Table 15. Novartis Company Information, Head Office, and Major Competitors
Table 16. Novartis Major Business
Table 17. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 18. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Novartis Recent Developments and Future Plans
Table 20. Immunicum Company Information, Head Office, and Major Competitors
Table 21. Immunicum Major Business
Table 22. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 23. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Immunicum Recent Developments and Future Plans
Table 25. Roche Company Information, Head Office, and Major Competitors
Table 26. Roche Major Business
Table 27. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 28. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Roche Recent Developments and Future Plans
Table 30. AB Science Company Information, Head Office, and Major Competitors
Table 31. AB Science Major Business
Table 32. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 33. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. AB Science Recent Developments and Future Plans
Table 35. Arog Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Arog Pharmaceuticals Major Business
Table 37. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 38. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Arog Pharmaceuticals Recent Developments and Future Plans
Table 40. Boston Biomedical Company Information, Head Office, and Major Competitors
Table 41. Boston Biomedical Major Business
Table 42. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 43. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Boston Biomedical Recent Developments and Future Plans
Table 45. Sun Pharmaceutical Company Information, Head Office, and Major Competitors
Table 46. Sun Pharmaceutical Major Business
Table 47. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 48. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Sun Pharmaceutical Recent Developments and Future Plans
Table 50. Natco Pharma Company Information, Head Office, and Major Competitors
Table 51. Natco Pharma Major Business
Table 52. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product and Solutions
Table 53. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Natco Pharma Recent Developments and Future Plans
Table 55. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (USD Million) by Players (2018-2023)
Table 56. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Share by Players (2018-2023)
Table 57. Breakdown of Gastrointestinal Stromal Tumors (GSTs) Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Gastrointestinal Stromal Tumors (GSTs) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Gastrointestinal Stromal Tumors (GSTs) Treatment Players
Table 60. Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Type Footprint
Table 61. Gastrointestinal Stromal Tumors (GSTs) Treatment Market: Company Product Application Footprint
Table 62. Gastrointestinal Stromal Tumors (GSTs) Treatment New Market Entrants and Barriers to Market Entry
Table 63. Gastrointestinal Stromal Tumors (GSTs) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Share by Type (2018-2023)
Table 66. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Forecast by Type (2024-2029)
Table 67. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023)
Table 68. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Forecast by Application (2024-2029)
Table 69. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Gastrointestinal Stromal Tumors (GSTs) Treatment Raw Material
Table 100. Key Suppliers of Gastrointestinal Stromal Tumors (GSTs) Treatment Raw Materials
List of Figures
Figure 1. Gastrointestinal Stromal Tumors (GSTs) Treatment Picture
Figure 2. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type in 2022
Figure 4. Surgery
Figure 5. Targeted Therapy
Figure 6. Radiation Therapy
Figure 7. ChemOthersapy
Figure 8. Others
Figure 9. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application in 2022
Figure 11. Hospitals Picture
Figure 12. Clinics Picture
Figure 13. Ambulatory Surgical Centers Picture
Figure 14. Others Picture
Figure 15. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Market Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 18. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 19. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Region in 2022
Figure 20. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 23. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Share by Players in 2022
Figure 26. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 27. Global Top 3 Players Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share in 2022
Figure 28. Global Top 6 Players Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share in 2022
Figure 29. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Share by Type (2018-2023)
Figure 30. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share Forecast by Type (2024-2029)
Figure 31. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Share by Application (2018-2023)
Figure 32. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Share Forecast by Application (2024-2029)
Figure 33. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 34. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 35. North America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 37. Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 38. Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 39. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 40. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 41. Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 42. Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. France Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 44. United Kingdom Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 45. Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 46. Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 47. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 48. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 49. Asia-Pacific Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 50. China Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 52. South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 53. India Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 54. Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 55. Australia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 56. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 57. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 58. South America Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 59. Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 60. Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 61. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 62. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 63. Middle East and Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 64. Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 65. Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 66. UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 67. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers
Figure 68. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Restraints
Figure 69. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Manufacturing Cost Structure Analysis of Gastrointestinal Stromal Tumors (GSTs) Treatment in 2022
Figure 72. Manufacturing Process Analysis of Gastrointestinal Stromal Tumors (GSTs) Treatment
Figure 73. Gastrointestinal Stromal Tumors (GSTs) Treatment Industrial Chain
Figure 74. Methodology
Figure 75. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Pfizer
Bayer
Novartis
Immunicum
Roche
AB Science
Arog Pharmaceuticals
Boston Biomedical
Sun Pharmaceutical
Natco Pharma
jiaGou

Add To Cart

gouMai

Buy Now